MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ
0.3998
-0.0002
-0.05%
Closed 13:00 11/25 EST
OPEN
0.3899
PREV CLOSE
0.4000
HIGH
0.4100
LOW
0.3872
VOLUME
115.10K
TURNOVER
15.77K
52 WEEK HIGH
1.390
52 WEEK LOW
0.3605
MARKET CAP
30.48M
P/E (TTM)
-0.6757
1D
5D
1M
3M
1Y
5Y
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Benzinga · 11/07 08:07
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Benzinga · 11/04 16:54
Hepion Pharmaceuticals dips after pricing $20M convertible preferred stock offering
Seekingalpha · 11/04 12:38
Hepion Pharmaceuticals Prices $20.0M Private Placement Of Convertible Redeemable Preferred Stock
Benzinga · 11/04 12:36
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, inc...
GlobeNewswire · 11/04 12:30
Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
EDISON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, inc...
GlobeNewswire · 11/02 12:00
BRIEF-Hepion Pharmaceuticals Announces Publication Of Phase 2A ‘Ambition’ Clinical Trial Results
Reuters · 10/26 12:18
Hepion Pharmaceuticals Announces Publication Of Phase 2a 'AMBITION' Clinical Trial Results; Co. Reports 'Study met safety, tolerability, and pharmacokinetics primary endpoints'
Benzinga · 10/26 12:07
More
About HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, Rencofilstat (formerly CRV431), is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. Rencofilstat is a pan cyclophilininhibitor that targets multiple pathologic pathways involved in the progression of liver disease. It provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.